The BEATsep project will apply an interdisciplinary approach bringing together research and clinical teams working on specific aspects of the development, treatment and prevention of the long-term consequences of sepsis and its impact on patients’ quality of life. Comprehensive clinical and research data generated during the project will be integrated using artificial intelligence algorithms into an easy-to-use predictive tool capable of identifying patients at high risk of complications. BioVariance GmbH is involved here in the development of algorithms that link these collected data. Furthermore, the consortium plans to design a tertiary prevention strategy to improve the recovery outcomes.

For the next five years, the consortium brings six European countries together in a joint mission to understand and fight the long consequences of sepsis.

The consortium is coordinated by ICRC-FNUSA and will consist of leading European institutions including: 1) CIML – Centre d’immunologie de Marseille-Luminy – (Aix-Marseille Université/CNRS/Inserm); 2) Institute of Innate Immunity, at the Medical Faculty of the University of Bonn, Germany; 3) Faculty of Medicine at the Comenius University in Slovakia; 4) Ludwig Boltzmann Institute for Traumatology, Vienna, Austria;  5) BioVariance GmbH, Germany; 6) Masaryk University, Brno, Czechia;  7) National Institute of Health, Prague, Czechia; 8) University of Galway and 9) APHM – Marseille Hospitals. BEATsep assembles renowned experts in immuno-metabolism and epigenetics, immunophenotyping, diagnostic research and several clinical teams treating adult and pediatric sepsis patients. “It has taken nearly two years of intensive preparation and networking to assemble the consortium. We used the advantage of bringing together teams with whom we have been already collaborating on several other projects.” says Dr. Marcela Hortová-Kohoutková from the CMI research group, who co-headed the project’s preparation.

In total, 9 partners from renowned European research and clinical institutions and 1 commercial partner in six EU countries will be involved in the BEATsep. “The project is an example of an innovative and successful combination of translational and clinical research, the know-how of several international scientists, and the collaboration between hospitals, universities and other scientific institutions.

For more information and updates:

www.beatsepsis.eu

https://shorturl.at/isRZ9 (LinkedIN)

Der Beitrag BioVariance is a partner in the EU-funded project “BEATsep”, which aims to combat the long-term effects of sepsis. erschien zuerst auf BioVariance - data-driven diagnostics.

Due to known difficulties and the long outdated topic, the antibody study will not take place as planned. We apologize for this and would be pleased if Ms. Schraml and BioVariance would nevertheless continue to support and participate in our first study on telomere length determination, which can be used to determine a person’s biological age.

Telomere length determination is a fascinating field of research that gives us information about the condition and health of our cells. Telomeres are the protective caps at the ends of our chromosomes that are associated with the aging process. By analyzing telomere lengths, our team can gain important insights into the biological aging process and thus determine biological age. With this telomere length determination study, we are once again setting the standard in medical research and reaffirming our position as a pioneer in the field of biomedical innovation.

To further this important research, we are seeking volunteers of either gender, 18 years of age or older, who are willing to have a sample of their oral mucosa taken with a simple cheek swab. This can be done on-site at our facility or at your home, using a so-called test kit (similar to a rapid PCR test), which we will send to you by mail.

The telomere length determination study will take place in July and offers you the opportunity to participate in groundbreaking research. Interested individuals are welcome to call 09631 / 30 89 200 or email studie@biovariance.com, stating your address, gender and age, for more information and to register to participate.

The results of this research could lead to new insights into the aging process and form the basis for future medical advances.

Der Beitrag Antibody study gives way to the telomere length study erschien zuerst auf BioVariance - data-driven diagnostics.

What is metastatic colorectal cancer?
The third most common type of cancer is colorectal cancer. mCRC is the metastatic type of colorectal cancer being located at the colon or rectal part of the human body. It appears more often in men than in women, but women often suffer from the more aggressive right-sided type of the cancer. The right-sided type of mCRC goes along with a worse prognosis of survival. Generally, one can distinguish between left- and right-sided colorectal cancer, where left-sided mCRC patients have better prognoses concerning the progression-free survival (PFS). The PFS is a factor that measures how long people survive after the cancer treatment without the tumor progressing again. A lot of mCRC cases are related to higher ages, because age is one of the risk factors. Other risk factors are a bad lifestyle (bad diet habits, alcohol consumption, etc) and less frequently also genetic factors.

Classification of mCRC patients is done by the oncologists on basis of anatomical tumor characteristics like grading and staging. Grading indicates how similar a tumor cell is to a normal cell, whereas staging gives information about the size and the spreading of the tumor. Since not all patients have the same present biomarkers (biologically measurable parameters of biological processes, that are known to have prognostic or diagnostic expressive power) and clinical data (measured values like weight, height, blood pressure, vitamin d value etc.), not all treatments will work equally well for all patients. Thus, a more personalized approach is being aspired, where in addition to grading and staging several other molecular biomarkers and individual clinical data of the patient play a more important role in the treatment decision.

What does REVERT mean?
The abbreviation REVERT origins from the long title “taRgeted thErapy for adVanced colorEctal canceR paTients”. REVERT is an international project funded by the EU, that started in 2020 and is planned to end in 2023. Specialists from Italy, Spain, Sweden, Luxembourg, Romania, and Germany were chosen to participate in the project, involving clinicians, pathologists, biologists, software developers, and also artificial intelligence (AI) specialists. BioVariance is part of the work package being responsible for the development of the AI solutions, thus BioVariance will offer some machine learning solutions for the question of the project.

What is the aim of the project?
The project aims at generating the REVERT database of molecular and clinical data collected from several hundred metastatic colorectal cancer patients that had visited one of the participating hospitals located at the different countries within the EU in the past. The database is then used as a basis for machine learning models to aspire a more personalized therapy approach for treating newly diagnosed patients. In the future, the trained AI model will predict a suitable first-line treatment for each new patient, who has not received any cancer medication yet, supporting the clinicians in their treatment decision. In addition to that, a clinical study will be executed with several new patients that decide to participate and want to be treated according to the AI-based results. This prospective clinical study will be performed with already authorized and commonly used chemotherapies and not with new treatments. The expectation concerning the AI-based results is to provide another more objective decision factor for clinicians, that is free from the subjective decision of the attending doctor at the hospital. Finally, the machine learning (ML) solutions will be combined in an app, that can support clinicians in the future.

What is machine learning and how is it used in the context of the project?
Machine learning algorithms use underlying mathematical models to recognize certain patterns in the patient’s data. The primary dataset of the REVERT database contains several processes of cancer treatments, the known survival outcome and about 150 other molecular and clinical features of hundreds of mCRC patients from the last 10 years. According to the underlying mathematical models, it is possible to derive some new rules from this dataset, that make it possible to predict outcomes for each new patient that was not included in the primary data. Therefore, the primary dataset must be used to (i) train and thereby generating ML models and to (ii) test and evaluate these generated models. In addition, the ML models allow to spot important features, that have a strong influence on the outcome prediction. For the primary dataset the actual outcome is already known, allowing us to see for how many patients the model predicted the correct outcome.

In the REVERT project BioVariance’s ML algorithms are used to create models that can classify whether a certain patient is likely to respond to different chemotherapies, that have been approved for years. During the project, several chemotherapies have already been categorized by the clinicians as being equally well for treating mCRC and that are now considered for the project. The related question for the ML algorithms is to predict the first-line treatment (= initial treatment, that is recommended for a disease, here: chemotherapy) having the highest chance of success for a certain patient.

What is the current status of the project and what is still to come?
At the moment, the machine learning models are already trained and tested on the previously collected dataset. BioVariance’s models and the models of three other REVERT members are used to predict the best first-line treatment for real patients participating in a phase two clinical study that started in March this year. The first few patients that were diagnosed with mCRC and enrolled to the study have already been processed with the ML models and were treated according to the model outcomes.

The main focus lays on the continuous improvement of the ML algorithms to get the best predictions possible. In the near future the ML models will be included into the REVERT app interface. This allows clinicians to directly enter patient’s data into the REVERT app and get a prediction for the most suitable first-line treatment on a patient-based level.

This approach is an important step into the direction of personalized medicine, since the huge amount of each patient’s data is intensively analyzed and leads to the best treatment for that patient individually, whereas in the current decision process patients get more or less grouped into stages or grades and are then treated in the same way. Finally, the clinical study will show whether the more personalized approach will be able to improve the survival of the patients.

Der Beitrag BioVariance is a member of the EU-funded REVERT Project erschien zuerst auf BioVariance - data-driven diagnostics.

BioVariance GmbH is a German company specializing in the analysis of health data. The company aims to improve everyone’s health by providing personalized medical recommendations based on big data analytics. Using Big Data analytics and artificial intelligence, BioVariance develops personalized health plans based on each patient’s individual needs.

Dr. Josef Scheiber, BioVariance’s founder and CEO, has been instrumental in the company’s success. His years of experience in health research and data analytics have enabled him to update BioVariance’s technology and develop innovative approaches to improve people’s health.

The CIO Views award is further testament to the excellence of Dr. Josef Scheiber and BioVariance. In a statement, Scheiber said, “I am honored to be recognized by CIO Views as one of the Most Innovative Leaders of 2023. This award is a testament to the commitment and passion we have at BioVariance for improving the health and well-being of every individual. We will continue to work hard to push the boundaries of health research and data analytics and develop innovative solutions to improve the health of people around the world.”

Overall, the CIO Views award is a testament to the innovation and dedication of Dr. Josef Scheiber and BioVariance. With their groundbreaking work in the field of health data analytics, they have the potential to change the future of medicine and improve the lives of millions of people worldwide.

Der Beitrag CIO Views honors Dr. Josef Scheiber as one of the most innovative executives in 2023 erschien zuerst auf BioVariance - data-driven diagnostics.

Further advantages of the technique lie in the ability to scan a single sample for many compounds, and the excellent data quality.

Our goal is to develop custom analyses for our cherished customers and collaborators on demand. Our vision is to extend the human lifespan by simplifying the treatment of complex diseases. In the future, cancer, infectious, neurodegenerative and mental diseases should be as easy to treat as a common cold.

At the moment, our highly skilled and trained personnel is implementing a test to accurately quantify a multitude of vitamins from as little as 20µL of blood (Vit Bs, Ds, A, E, K). Feel free to contact us for more information.

Der Beitrag Investment in high precision diagnostics erschien zuerst auf BioVariance - data-driven diagnostics.

The opening marks an important milestone for BioVariance GmbH as it underscores the growth and expansion of the company, which aims to extend the human lifespan by simplifying the treatment of complex diseases. In the future, cancer, infectious, neurodegenerative and mental diseases should be as easy to treat as a normal cold.

The move is accompanied by a brand relaunch that emphasizes BioVariance’s commitment to improving people’s quality of life by better treating disease. Since its founding in 2013, the company has worked closely with the Bavarian Red Cross, diagnostic and pharmaceutical companies, universities and colleges, and various patient organizations to achieve this goal.

“We have worked hard to update our branding to ensure it reflects our commitment to improving human health,” said Dr. Josef Scheiber. “Our new brand image reflects our goal to make disease as treatable as the common cold. We look forward to working in our new facility and continuing our work to improve people’s quality of life.”

Der Beitrag BioVariance opens new offices and presents itself with a new logo erschien zuerst auf BioVariance - data-driven diagnostics.